Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - fiercepharma.com
Glenmark faces a recall and a warning letter due to inadequate investigation of a manufacturing issue, potentially impacting compliance and operational integrity.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, particularly those involved in tablet production. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action is recommended to prevent similar issues.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Glenmark's recall and warning letter highlight the consequences of failing to meet FDA standards for good manufacturing practices (cGMP).
Who it affects
All pharmaceutical manufacturers, particularly those involved in tablet production.
What you must do
Review and enhance internal quality control processes to ensure compliance with cGMP standards.
Deadline
Immediate action is recommended to prevent similar issues.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Warning Letter for Refusal to Permit Inspection: Important Takeaways for Startups and Drug and Device Manufacturers - wsgr.com
- Michigan law shielding drug makers draws scrutiny amid opioid crisis - detroitnews.com
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - kff.org
- FDA Declares PFAS Polymers in Medical Devices Safe and Currently Irreplaceable - afslaw.com